Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Glioblastoma and Chemoresistance to Alkylating Agents: Involvement of Apoptosis, Autophagy, and Unfolded Protein Response Publisher Pubmed



Hombachklonisch S1 ; Mehrpour M2, 3 ; Shojaei S1, 4 ; Harlos C5, 6 ; Pitz M5, 6 ; Hamai A2, 3 ; Siemianowicz K7 ; Likus W8 ; Wiechec E9 ; Toyota BD10 ; Hoshyar R11, 12 ; Seyfoori A13 ; Sepehri Z1, 14 ; Ande SR15 Show All Authors
Authors
  1. Hombachklonisch S1
  2. Mehrpour M2, 3
  3. Shojaei S1, 4
  4. Harlos C5, 6
  5. Pitz M5, 6
  6. Hamai A2, 3
  7. Siemianowicz K7
  8. Likus W8
  9. Wiechec E9
  10. Toyota BD10
  11. Hoshyar R11, 12
  12. Seyfoori A13
  13. Sepehri Z1, 14
  14. Ande SR15
  15. Khadem F16
  16. Akbari M13
  17. Gorman AM17, 18
  18. Samali A17, 18
  19. Klonisch T1, 6
  20. Ghavami S1, 19

Source: Pharmacology and Therapeutics Published:2018


Abstract

Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB. © 2017 Elsevier Inc.
Other Related Docs